Propionate life

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the launch of AirDuo™ RespiClick® and its Authorized Generic, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

No metabolites of fluticasone propionate were detected in an in vitro study of radiolabeled fluticasone propionate incubated in a human skin homogenate. The total blood clearance of systemically absorbed fluticasone propionate averages 1,093 mL/min (range, 618 to 1,702 mL/min) after a 1-mg intravenous dose, with renal clearance accounting for less than % of the total. Fluticasone propionate is metabolized in the liver by cytochrome P450 3A4-mediated hydrolysis of the 5- fluoromethyl carbothioate grouping. This transformation occurs in 1 metabolic step to produce the inactive17-ß-carboxylic acid metabolite, the only known metabolite detected in man. This metabolite has approximately 2,000 times less affinity than the parent drug for the glucocorticoid receptor of human lung cytosol in vitro and negligible pharmacological activity in animal studies. Other metabolites detected in vitro using cultured human hepatoma cells have not been detected in man.

Although patients receiving systemic corticosteroid therapy are more susceptible to secondary infection than patients not receiving corticosteroids, administration via the inhaled route minimizes this risk. Corticosteroid therapy can mask the symptoms of infection and should not be used in cases of bacterial, fungal, or viral infections that are not adequately controlled by anti-infective agents, except in life-threatening circumstances. Fluticasone; salmeterol should be avoided in patients with tuberculosis infections of the respiratory tract if possible. The incidence or course of acute bacterial or viral infection is probably minimally affected by inhaled corticosteroids in immunocompetent individuals; however, close monitoring of patients with immunosuppression is recommended if treatment with an inhaled corticosteroid is necessary.

Important Safety Information for Clobex ® (clobetasol propionate) Lotion, %
Clobex ® (clobetasol propionate) Lotion, %, is not recommended for anyone younger than 18 years of age.

Clobex ® Lotion is indicated to treat steroid-responsive dermatoses. Treatment of steroid responsive dermatoses (eczema, dermatitis) should be limited to 2 weeks. Use only as directed by your physician, and do not apply to your face, underarms, or groin and avoid contact with your eyes and lips.

The total dosage should not exceed 50 g (50 mL or fl oz) per week. You should use Clobex ® Lotion only for the minimum period necessary to achieve desired results. In clinical trials, patients reported burning/stinging, skin dryness, irritation, redness, itching, skin thinning and widening of blood vessels. Because too much Lotion passing through your skin may affect your adrenal glands, do not use more than prescribed and stop using the product if you experience nausea, vomiting, fever or low blood pressure, and call you doctor. If you are pregnant, trying to get pregnant or nursing, speak to your doctor before using Clobex ® Lotion.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit /medwatch , or call 1-800-FDA-1088 (1-800-332-1088).

“Field Crop News” is an archive of information dedicated to the production of over million acres of field crops in Ontario and a forum for which producers, researchers and industry personnel can share information and ideas. The crop technology team with the Ontario Ministry of Agriculture, Food and Rural Affairs (OMAFRA), faculty at the University of Guelph and Ontario field crop producers continually work together to find ways to improve field crop production. The key learning and outcomes from these collaborations are captured at “Field Crop News”.

Propionate life

propionate life

Important Safety Information for Clobex ® (clobetasol propionate) Lotion, %
Clobex ® (clobetasol propionate) Lotion, %, is not recommended for anyone younger than 18 years of age.

Clobex ® Lotion is indicated to treat steroid-responsive dermatoses. Treatment of steroid responsive dermatoses (eczema, dermatitis) should be limited to 2 weeks. Use only as directed by your physician, and do not apply to your face, underarms, or groin and avoid contact with your eyes and lips.

The total dosage should not exceed 50 g (50 mL or fl oz) per week. You should use Clobex ® Lotion only for the minimum period necessary to achieve desired results. In clinical trials, patients reported burning/stinging, skin dryness, irritation, redness, itching, skin thinning and widening of blood vessels. Because too much Lotion passing through your skin may affect your adrenal glands, do not use more than prescribed and stop using the product if you experience nausea, vomiting, fever or low blood pressure, and call you doctor. If you are pregnant, trying to get pregnant or nursing, speak to your doctor before using Clobex ® Lotion.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit /medwatch , or call 1-800-FDA-1088 (1-800-332-1088).

Media:

propionate lifepropionate lifepropionate lifepropionate lifepropionate life